ATC Abstracts

American Transplant Congress abstracts

2017 American Transplant Congress

April 29-May 3, 2017 in Chicago, IL

View by Title View Sessions
View by Date

Sunday, April 30, 2017

3:06pm-3:18pm
Efficacy and Safety of ASP0113 versus Placebo in CMV-Seronegative Kidney Transplant Patients Receiving an Organ from a CMV-Seropositive Donor.

F. Vincenti,1 K. Budde,2 P. Merville,3 F. Shihab,4 V. Peddi,5 M. Shah,6 E. Cassuto-Viguier,7 A. Weidemann,8,9 M. Lee,10 T. Flegel,10 J. Erdman,10 X. Wang,10 C. Lademacher.10

Concurrent Session: Cutting Edge - Cytomegalovirus  •  E353C
3:06pm-3:18pm
Efficacy and Safety of Everolimus with Reduced Tacrolimus or Cyclosporine in Pediatric Liver Transplant Recipients: 12-Month Results from H2305 Study.

A. Weymann,1 R. Ganschow,1 B. Ericzon,1 A. Dhawan,1 K. Sharif,1 E.-D. Martzloff,2 B. Rauer,2 J. Ng,2 P. Lopez.2

Concurrent Session: Pediatric Liver  •  E271a
3:06pm-3:18pm
Genome-Wide Genotyping in 1022 Heart Transplantation Recipients & 758 Donors Reveal Association with Acute Allograft Rejection.

J. van Setten,1 B. Cole,2 B. Chang,2 N. de Jonge,1 M. Holmes,2 C. Baan,4 O. Manintveld,4 A. Peeters,4 F. Dominguez,5 K. Khush,3 P. Garcia-Pavia,5 M. Huibers,1 R. de Weger,1 J. Moore,2 F. Asselbergs,1 B. Keating.2

Concurrent Session: Predicting Tolerance and Rejection  •  E351
3:06pm-3:18pm
Impact of Antihypertensive (AHT) Choice and Advagraf® Dose on Immunologic Events in Renal Allografts 24 Months Post-Transplantation (Tx).

D. Rush,1 S. Cockfield,2 S. Wilson,3 J. Howell,4 FKC-014 Study Group.

Concurrent Session: Novel Immunosuppression Regimens - Tacrolimus Combinations  •  E450b
3:06pm-3:18pm
Is Peri-Transplant Plasmapheresis Effective in the Prevention of Recurrence of FSGS?

P. Verghese, M. Rheault, S. Chinnakotla, S. Jackson, A. Matas, B. Chavers.

Concurrent Session: Kidney: Pediatric Immune Injury and Recurrent Disease  •  E451a
3:06pm-3:18pm
Long-Term Liver and Kidney Survival Following Combined Liver-Kidney Transplantation, with or without Preformed Donor-Specific Antibodies.

A. Del Bello,1 O. Bestard,2 J. Visentin,3 N. Congy-Jolivet,1 L. Couzi,3 M. Neau-Cransac,3 F. Jambon,3 N. Kamar.1

Concurrent Session: Assessing Risk for Antibody-Mediated Rejection in Kidney Transplant Recipients  •  E354a
3:06pm-3:18pm
Outcomes of Protocol Allograft Kidney Biopsy in DeNovo Donor Specific Antibodies.

S. Parajuli, P. Reville, T. Ellis, A. Djamali, D. Mandelbrot.

Concurrent Session: Kidney HLA Antibodies  •  E354b
3:06pm-3:18pm
Post-Donation Remaining Donor Kidney Function as Measured by CKD-EPI Formula at 2 Years Correlates and Is Predicted by Remaining Donor Kidney Volume.

S. Hussain, A. Diez, A. Khalil, M. Yaqub, D. Mishear, T. Taber, O. Adebiyi, C. Sundaram, W. Goggins, J. Powelson, A. Sharfuddin.

Concurrent Session: Kidney Living Donor Evaluation and Recruitment  •  E450a
3:06pm-3:18pm
Precise Antibody Characterization Using Multiple Solid Phase Assay Platforms Is Critical for Accurate Virtual Crossmatching.

D. Li,1 O. Timofeeva,1 M. Awwad,1 C. Cody,2 S. Najjar,2 S. Rosen-Bronson.1

Concurrent Session: Heart Waitlist and Allocation: Working to Get It Right  •  E267
3:06pm-3:18pm
Tacrolimus Intra-Patient Variability Determined from Daily Trough Levels in Adherent Kidney and Liver Transplant Recipients.

A. Leino,1 T. Kaiser,1 Y. Zou,2 E. King,2 A. Vinks,2 W. Jiang,4 U. Christians,3 E. Woodle,1 R. Alloway.1

Concurrent Session: Psychosocial and Mediation Adherence Concerns  •  E271b